Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zentek ( (TSE:ZEN) ) just unveiled an update.
On August 26, 2025, Zentek Ltd. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its shares have been below US $1.00 for 31 consecutive business days. This notification does not immediately affect the trading of Zentek’s shares, and the company has 180 days to regain compliance. If necessary, Zentek may consider a reverse stock split to meet the requirements. The company’s business operations remain unaffected by this notification.
The most recent analyst rating on (TSE:ZEN) stock is a Sell with a C$1.00 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Underperform.
Zentek’s overall stock score is significantly impacted by its poor financial performance, bearish technical indicators, and unattractive valuation. The company’s ongoing profitability challenges, negative cash flows, and lack of positive market momentum contribute to a low score. Without any earnings call insights or notable corporate events to offset these issues, the stock remains a high-risk investment.
To see Spark’s full report on TSE:ZEN stock, click here.
More about Zentek
Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company that focuses on the research, development, and commercialization of novel products. The company aims to provide its commercial partners with a competitive advantage by enhancing the safety, efficiency, and environmental friendliness of their products. Zentek’s patented technology platform, ZenGUARD™, is designed to offer high anti-microbial activity and improve viral filtration efficiency in surgical masks and HVAC systems. Additionally, through its subsidiary Triera Biosciences Ltd., Zentek holds a global exclusive license for an aptamer-based platform technology developed in collaboration with McMaster University for diagnostic and therapeutic markets.
Average Trading Volume: 50,451
Technical Sentiment Signal: Sell
Current Market Cap: C$91.1M
For an in-depth examination of ZEN stock, go to TipRanks’ Overview page.